Developing novel biopharmaceuticals
TRIM-edicine is an early-stage, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of several important unmet medical needs, including oral healthcare, dermal wounds, ischemia/reperfusion injury, sports medicine and muscular dystrophy. The company is built around a core of protein therapeutic approaches that involve novel proteins with remarkable biological properties. These unique proteins target a variety of cellular pathways that are altered in numerous disease states.
R&D efforts at TRIM-edicine focus on providing proof-of-concept support to validate our technology and facilitate partnerships with various established companies in the biomedical field.
Our Mission
TRIM-edicine will lead the field of protein therapeutics for regenerative medicine by developing treatments for unmet biomedical needs, including traumatic injury, environmental insults, genetic disorders and chronic diseases.